{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:09:42Z","timestamp":1788811782546,"version":"build-2803163510"},"reference-count":31,"publisher":"Institute of Physiology of the Czech Academy of Sciences","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Pulsed-field ablation (PFA) has become an important non-thermal modality for pulmonary vein isolation in atrial fibrillation (AF), characterized by myocardial selectivity and reduced collateral tissue injury. However, the physiological biomarker response to PFA remains incompletely defined. This study assessed serial changes in myocardial (troponin T, creatine kinase - CK and its isoenzyme - CK-MB) and renal (urea, creatinine) biomarkers in patients undergoing PFA at a single center and compared these findings with current clinical evidence. The study cohort consisted of 52 patients undergoing PFA (73 % men, 27 % women), with 52 % presenting paroxysmal AF and 48 % persistent AF. The mean left atrial diameter was 45 \u00b1 7 mm and the average left ventricular ejection fraction was 55 \u00b1 7 % The mean ablation burden was 67 \u00b1 23 applications per procedure. Biomarkers were measured before and after ablation. Repeated-measures ANOVA demonstrated significant time effects for all myocardial biomarkers (p &lt; 0.001) and significant interactions with ablation burden. Troponin-T increased from near-zero baseline values to markedly elevated levels immediately and 24-hours after the procedure, while CK and CK-MB rose several-fold with only partial decline after the procedure. In contrast, urea and creatinine remained stable, indicating preserved renal function without acute kidney injury. The number of PFA applications correlated positively with late CK and CK-MB values, suggesting that myocardial biomarker load scales with procedural intensity. These findings align with current literature showing extensive myocardial biorelease after PFA but favorable extracardiac safety. By concurrently analyzing myocardial and renal markers, this study demonstrates that substantial biochemical myocardial injury induced by PFA does not translate into measurable renal dysfunction. Overall, PFA appears physiologically consistent with a profile of robust but targeted myocardial injury and preserved renal safety.<\/jats:p>","DOI":"10.33549\/physiolres.935802","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:16:11Z","timestamp":1788808571000},"page":"667","source":"Crossref","is-referenced-by-count":0,"title":["Physiological Tissue Response to Pulsed-Field Ablation for Atrial Fibrillation: Insights from Biomarker Kinetics"],"prefix":"10.33549","volume":"75","author":[{"given":"Karol","family":"Zdraveck\u00fd","sequence":"first","affiliation":[{"name":"Department of Arrhythmology, Clinic of Cardiology and Angiology, Kardiocentrum AGEL, Ko\u0161ice-\u0160aca, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Zembjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Farka\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mi\u0161\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tVerma A, Haines DE, Boersma LV, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation. 2023;147(18):1422-1432. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.063988","DOI":"10.1161\/CIRCULATIONAHA.123.063988"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tReddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation. JACC Clin Electrophysiol. 2021;7(5):614-627. https:\/\/doi.org\/10.1016\/j.jacep.2021.02.014","DOI":"10.1016\/j.jacep.2021.02.014"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tEkanem E, Neuzil P, Reichlin T, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation: the MANIFEST-17K study. Nat Med. 2024;30(8):2020-2029. https:\/\/doi.org\/10.1038\/s41591-024-03114-3","DOI":"10.1038\/s41591-024-03114-3"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tLakkireddy D, Anic A, Koruth JS, et al. Collateral tissue injury and safety outcomes of pulsed field ablation: the NEMESIS-PFA study. JACC Clin Electrophysiol. 2025;11(3):1747-1756. https:\/\/doi.org\/10.1016\/j.jacep.2025.04.017","DOI":"10.1016\/j.jacep.2025.04.017"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tGill JS, Gallagher MM, Sagar V, et al. Dressler's syndrome after pulsed field ablation for atrial fibrillation: a case report. HeartRhythm Case Rep. 2025;11(8):812-815. https:\/\/doi.org\/10.1016\/j.hrcr.2025.05.026","DOI":"10.1016\/j.hrcr.2025.05.026"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tPopa MA, Bahlke F, Kottmaier M, et al. Myocardial injury and inflammation following pulsed-field ablation and very high-power short-duration ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2024;35(2):317-327. https:\/\/doi.org\/10.1111\/jce.16157","DOI":"10.1111\/jce.16157"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tOsmancik P, Bacova B, Hozman M, et al. Myocardial damage, inflammation, coagulation, and platelet activity during catheter ablation using radiofrequency and pulsed-field energy. JACC Clin Electrophysiol. 2024;10(3):463-474. https:\/\/doi.org\/10.1016\/j.jacep.2023.11.001","DOI":"10.1016\/j.jacep.2023.11.001"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tKrisai P, Knecht S, Badertscher P, et al. Troponin release after pulmonary vein isolation using pulsed field ablation compared with radiofrequency and cryoballoon ablation. Heart Rhythm. 2022;19(9):1471-1472. https:\/\/doi.org\/10.1016\/j.hrthm.2022.05.020","DOI":"10.1016\/j.hrthm.2022.05.020"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tFeickert H, Urbanek L, Bordignon S, et al. Impact of renal function on troponin release after pulsed field versus cryoballoon ablation. Eur J Med Res. 2025;30:700. https:\/\/doi.org\/10.1186\/s40001-025-02964-y","DOI":"10.1186\/s40001-025-02964-y"},{"key":"ref9","unstructured":"10.\tCasella M, Compagnucci P, Malacrida M, et al. Multiple cardiac biomarkers during different pulsed field ablation technologies compared with radiofrequency ablation. Heart Rhythm O2. 2025;6(10):1688-1695."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tWenzel JP, Hatahet S, Abdessadok R, Eitel C, Nikorowitsch J, Mamaev R, Reincke S, Popescu S, Traub A, de Waha S, Zeller T, Kuck KH, Tilz RR. Differential inflammatory and myocardial biomarker response after pulsed field ablation for atrial fibrillation using balloon-in-basket vs pentaspline catheters. Heart Rhythm O2. 2025;6(12):1861-1869 https:\/\/doi.org\/10.1016\/j.hroo.2025.09.003. Epub ahead of print.","DOI":"10.1016\/j.hroo.2025.09.003"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tKatic J, Mohr FW, Etz CD, et al. Pulsed-field ablation is associated with lower endothelial injury and shorter procedure time compared with cryoballoon ablation. Pathophysiology. 2025;32(1):60-72. https:\/\/doi.org\/10.3390\/pathophysiology32040060","DOI":"10.3390\/pathophysiology32040060"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tOsmancik P, Bacova B, Herman D, et al. Periprocedural intravascular hemolysis during atrial fibrillation ablation: comparison of pulsed field and radiofrequency energy. JACC Clin Electrophysiol. 2024;10(12):1660-1671. https:\/\/doi.org\/10.1016\/j.jacep.2024.05.001","DOI":"10.1016\/j.jacep.2024.05.001"},{"key":"ref13","unstructured":"14.\tYoshizawa R. Hemolysis-related acute kidney injury after pulsed field ablation: An emerging"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"concern in patients with hematologic disorders. HeartRhythm Case Rep. 2025;11(10):976-977. https:\/\/doi.org\/10.1016\/j.hrcr.2025.08.016","DOI":"10.1016\/j.hrcr.2025.08.016"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15.\tWenzel JP, Abdessadok R, Eitel C, Vogler J, Hatahet S, Nikorowitsch J, Mamaev R, Popescu S, Yaman E, \u00d6zalp TA, Reincke S, Traub A, K\u00fcchler M, Kuck KH, Tilz RR. Catheter Design Matters: Hemolysis and Renal Function after Pulsed Field Ablation with Balloon-in-Basket vs. Pentaspline Systems. J Interv Card Electrophysiol (2025). https:\/\/doi.org\/10.1007\/s10840-025-02152-2","DOI":"10.1007\/s10840-025-02152-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16.\tSawada M, Nagashima K, Watanabe R, Saito Y, Wakamatsu Y, Otsuka N, Hirata S, Hirata M, Kurokawa S, Ito S, Otake S, Miura K, Nakamura H, Okumura Y. Acute kidney injury after pulsed field ablation in a patient with Waldenstr\u00f6m's macroglobulinemia: A case report. HeartRhythm Case Rep. 2025;11(10):973-975. https:\/\/doi.org\/10.1016\/j.hrcr.2025.08.007. Epub ahead of print.","DOI":"10.1016\/j.hrcr.2025.08.007"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17.\tHartl S, Reinsch N, F\u00fcting A, Neven K. Pearls and pitfalls of pulsed field ablation. Korean Circ J. 2023;53(4):273-293. https:\/\/doi.org\/10.4070\/kcj.2023.0023","DOI":"10.4070\/kcj.2023.0023"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18.\tCasciola M, Keck D, Feaster TK, Blinova K. Human cardiomyocytes are more susceptible to irreversible electroporation than oesophageal cells. Physiol Rep. 2022;10(6):e15493. https:\/\/doi.org\/10.14814\/phy2.15493","DOI":"10.14814\/phy2.15493"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"19.\tBaena-Montes JM, Clarke C, Quinlan LR, et al. Electroporation parameters for human cardiomyocyte ablation in vitro. J Cardiovasc Dev Dis. 2022;9(8):240. https:\/\/doi.org\/10.3390\/jcdd9080240","DOI":"10.3390\/jcdd9080240"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20.\tKos B, Mattison L, Ramirez D, et al. Lethal electric field threshold for pulsed field ablation in ex vivo porcine and human hearts. Front Cardiovasc Med. 2023;10:1160231. https:\/\/doi.org\/10.3389\/fcvm.2023.1160231","DOI":"10.3389\/fcvm.2023.1160231"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21.\tJiang S, Qian F, Ji S, et al. Pulsed field ablation for atrial fibrillation: mechanisms, advantages, and limitations. Rev Cardiovasc Med. 2024;25(4):138. https:\/\/doi.org\/10.31083\/j.rcm2504138","DOI":"10.31083\/j.rcm2504138"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22.\tSullivan AP, Aguilar M, Laksman Z. Pulsed field ablation: a review of preclinical and clinical studies. Bioengineering (Basel). 2025;12(4):329. https:\/\/doi.org\/10.3390\/bioengineering12040329","DOI":"10.3390\/bioengineering12040329"},{"key":"ref23","unstructured":"23.\tVerma A, Boersma L, Haines DE, et al. Evaluation of a novel nonthermal pulsed field ablation system for pulmonary vein isolation: safety and feasibility study. Circ Arrhythm Electrophysiol. 2018;11(8):e006338."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24.\tChun KRJ, Schmidt B, Metzner A, et al. State-of-the-art pulsed field ablation for cardiac arrhythmias. Europace. 2024;26(5):euae086. https:\/\/doi.org\/10.1093\/europace\/euae134","DOI":"10.1093\/europace\/euae134"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25.\tEzzeddine FM, Kaneshiro T, Reddy VY. Pulsed field ablation: a comprehensive update. J Cardiovasc Electrophysiol. 2024;35(8):2031-2046. https:\/\/doi.org\/10.3390\/jcm13175191","DOI":"10.3390\/jcm13175191"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26.\tNapotnik TB, Polajzer T, Miklav\u010di\u010d D. Cell death due to electroporation-A review. Bioelectrochemistry. 2021;141:107871. https:\/\/doi.org\/10.1016\/j.bioelechem.2021.107871","DOI":"10.1016\/j.bioelechem.2021.107871"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27.\tBaena-Montes JM, et al. Electroporation parameters for human cardiomyocyte irreversible electroporation in vitro. Bioengineering (Basel). 2022;9(8):350. https:\/\/doi.org\/10.3390\/jcdd9080240","DOI":"10.3390\/jcdd9080240"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28.\tMiklav\u010di\u010d D, et al. Biophysics and electrophysiology of pulsed field ablation in cardiac tissue. Sci Rep. 2024;14:83683. https:\/\/doi.org\/10.1038\/s41598-024-83683-y","DOI":"10.1038\/s41598-024-83683-y"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29.\tTabaja C, Mdaihly M, Noujaim C, Wazni OM, Santangeli P. Tissue selectivity of pulsed field ablation. J Cardiovasc Electrophysiol. 2025;36(6):1510-1520. https:\/\/doi.org\/10.1016\/j.ccep.2025.02.003","DOI":"10.1016\/j.ccep.2025.02.003"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30.\tCasciola M, Keck D, Feaster TK, Blinova K. Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells. Physiol Rep. 2022;10:e15493. https:\/\/doi.org\/10.14814\/phy2.15493","DOI":"10.14814\/phy2.15493"}],"container-title":["Physiological Research"],"original-title":[],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:16:15Z","timestamp":1788808575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2026\/75_667.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.33549\/physiolres.935802","relation":{},"ISSN":["1802-9973"],"issn-type":[{"value":"1802-9973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}